- Home
- IMNN vs PYPD Comparison
IMNN vs PYPD Comparison
Compare IMNN & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNN
- PYPD
- Stock Information
- Founded
- IMNN 1982
- PYPD 2008
- Country
- IMNN United States
- PYPD Israel
- Employees
- IMNN N/A
- PYPD N/A
- Industry
- IMNN Biotechnology: Pharmaceutical Preparations
- PYPD Medical/Dental Instruments
- Sector
- IMNN Health Care
- PYPD Health Care
- Exchange
- IMNN Nasdaq
- PYPD Nasdaq
- Market Cap
- IMNN 12.1M
- PYPD 35.3M
- IPO Year
- IMNN 1985
- PYPD 2020
- Fundamental
- Price
- IMNN $0.79
- PYPD $3.59
- Analyst Decision
- IMNN Buy
- PYPD Strong Buy
- Analyst Count
- IMNN 2
- PYPD 5
- Target Price
- IMNN $14.00
- PYPD $11.40
- AVG Volume (30 Days)
- IMNN 3.9M
- PYPD 1.4M
- Earning Date
- IMNN 08-13-2025
- PYPD 08-13-2025
- Dividend Yield
- IMNN N/A
- PYPD N/A
- EPS Growth
- IMNN N/A
- PYPD N/A
- EPS
- IMNN N/A
- PYPD N/A
- Revenue
- IMNN N/A
- PYPD N/A
- Revenue This Year
- IMNN N/A
- PYPD N/A
- Revenue Next Year
- IMNN N/A
- PYPD N/A
- P/E Ratio
- IMNN N/A
- PYPD N/A
- Revenue Growth
- IMNN N/A
- PYPD N/A
- 52 Week Low
- IMNN $0.37
- PYPD $2.30
- 52 Week High
- IMNN $3.65
- PYPD $4.49
- Technical
- Relative Strength Index (RSI)
- IMNN 40.14
- PYPD 59.00
- Support Level
- IMNN $0.93
- PYPD $3.12
- Resistance Level
- IMNN $1.03
- PYPD $3.75
- Average True Range (ATR)
- IMNN 0.18
- PYPD 0.29
- MACD
- IMNN -0.10
- PYPD 0.01
- Stochastic Oscillator
- IMNN 1.39
- PYPD 69.83
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).
About PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.